KRT5 and neoplasm: To characterise the molecular profile of the TNBC patient cohort, the expression of the biomarkers CK5/6, EGFR, P-cadherin, AR, sLeX/A, and E-SL were measured in tumour sections by immunohistochemistry (Figure 1, Table 1).